Genetic Change of Varicella-Zoster Virus Propagated in Cell Culture in Non-Natural Conditions

Sang Hoon Yeon, Ji Seon Park, Se Hwan Kang, Chan Hee Lee

doi:10.4167/jbv.2021.51.4.178

All Issue

2021 Vol.51, Issue 4 Preview Page Next Page

Original Article

Genetic Change of Varicella-Zoster Virus Propagated in Cell Culture in Non-Natural Conditions

31 December 2021. pp. 178-188

PDF XML

Abstract

Primary infection of varicella-zoster virus (VZV) causes varicella and often leads to zoster after reactivation from latency. Both varicella and zoster can be prevented by live attenuated vaccines, but the molecular mechanism of attenuation is not clearly understood. In this study, it was attempted to understand mechanism of attenuating mutation in VZV by in vitro propagation in non-natural conditions such as low temperature or non-human cell. Clinical strain YC02 was subcultured in vitro up to 60 times. Comparison of the genome sequences of YC02 variants cultured under various conditions identified specific mutations occurred in non-natural conditions. The mutations specific for low temperature culture and non-human cell culture were identified in 8 and 2 positions, respectively. Two vaccine-specific mutations in position 97748 and 106262 were identified during subculture in non-natural conditions. Genetic diversity as measured by genetic polymorphism and Shannon entropy decreased when cultured in guinea pig lung cell culture. The infectivity of YC02 cultured at low temperature appeared similar to that cultured in natural condition. On the other hands, infectivity decreased significantly when YC02 was subcultured in non-human cell. Further studies on mutations and genetic diversity of clinical strain cultured in non-natural conditions will help to elucidate the molecular mechanism of VZV attenuation.

Keywords

Varicella-zoster virus

Vaccine

Low temperature culture

Non-human cell culture

Mutation

Genetic diversity

References

Davison AJ, Scott JE. The complete DNA sequence of varicella-zoster virus. J Gen Virol 1986;67:1759-816.

10.1099/0022-1317-67-9-17593018124

Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev 2013;26:728-43.

10.1128/CMR.00052-1324092852PMC3811230

Zerboni L, Sen N, Oliver SL, Arvin AM. Molecular mechanisms of varicella zoster virus pathogenesis. Nat Rev Microbiol 2014;12:197-210.

10.1038/nrmicro321524509782PMC4066823

Arvin AM, Moffat JF, Sommer M, Oliver S, Che X, Vleck S, et al. Varicella-zoster virus T cell tropism and the pathogenesis of skin infection. Curr Top Microbiol Immunol 2010;342:182-209.

10.1007/82_2010_2920397071PMC4077053

Gilden DH, Kleinschmidt-DeMasters BK, Laguardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000;342:635-45.

10.1056/NEJM20000302342090610699164

Kennedy PGE, Gershon AA. Clinical features of varicella-zoster virus infection. Viruses 2018;10:609.

10.3390/v1011060930400213PMC6266119

Hall S, Maupin T, Seward J, Jumaan AO, Peterson C, Goldman G, et al. Second varicella infections: are they more common than previously thought? Pediatrics 2002;109:1068-73.

10.1542/peds.109.6.106812042544

Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2:1288-90.

10.1016/S0140-6736(74)90144-5

D'Hondt E, Berge E, Colinet G, Duchene M, Peetermans J. Production and quality control of the Oka-strain live varicella vaccine. Postgrad Med J 1985;61:53-6.

Freer G, Pistello M. Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies. New Microbiol 2018;41:95-105.

Gershon AA. The current status of live attenuated varicella vaccine. Arch Virol Suppl 2001;1-6.

10.1007/978-3-7091-6259-0_111339539

Sohn YM, Park CY, Hwang KK, Woo GJ, Park SY. Safety and immunogenicity of live attenuated varicella virus vaccine (MAV/06 strain). J Korean Ped 1994;37:1405-13.

Jeon JS, Won YH, Kim IK, Ahn JH, Shin OS, Kim JH, et al. Analysis of single nucleotide polymorphism among varicella-zoster virus and identification of vaccine-specific sites. Virology 2016;496:277-86.

10.1016/j.virol.2016.06.01727376245

Cricca M, Morselli-Labate AM, Venturoli S, Ambretti S, Gentilomi GA, Gallinella G, et al. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol 2007;106:549-57.

10.1016/j.ygyno.2007.05.00417568661

Schmutzhard J, Merete Riedel H, Zweygberg Wirgart B, Grillner L. Detection of herpes simplex virus type 1, herpes simplex virus type 2 and varicella-zoster virus in skin lesions. Comparison of real-time PCR, nested PCR and virus isolation. J Clin Virol 2004;29:120-6.

10.1016/S1386-6532(03)00113-6

Hedrick PW. Genetics of population. Jones and Bartlett publishers 2010;103-5.

Gregori J, Perales C, Rodriguez-Frias F, Esteban JI, Quer J, Domingo E. Viral quasispecies complexity measures. Virology 2016;493:227-37.

10.1016/j.virol.2016.03.01727060566

Baudoux L, Defechereux P, Schoonbroodt S, Merville MP, Rentier B, Piette J. Mutational analysis of varicella-zoster virus major immediate-early protein IE62. Nucleic Acids Res 1985;23:1341-9.

10.1093/nar/23.8.13417753624PMC306859

Barrett-Muir W, Hawrami K, Clarke J, Breuer J. Investigation of varicella-zoster virus variation by heteroduplex mobility assay. Arch Virol Suppl 2001;17-25.

10.1007/978-3-7091-6259-0_311339546

Sen N, Sommer M, Che X, White K, Ruyechan WT, Arvin AM. Varicella-zoster virus immediate-early protein 62 blocks interferon regulatory factor 3 (IRF3) phosphorylation at key serine residues: a novel mechanism of IRF3 inhibition among herpesviruses. J Virol 2010;84:9240-53.

10.1128/JVI.01147-1020631144PMC2937611

Gomi Y, Sunamachi H, Mori Y, Nagaike K, Takahashi M, Yamanishi K. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol 2002;76:11447-59.

10.1128/JVI.76.22.11447-11459.200212388706PMC136748

Tillieux SL, Halsey WS, Thomas ES, Voycik JJ, Sathe GM, Vassilev V. Complete DNA sequences of two oka strain varicella-zoster virus genomes. J Virol 2008;82:11023-44.

10.1128/JVI.00777-0818787000PMC2573284

Quinlivan M, Breuer J. Clinical and molecular aspects of the live attenuated Oka varicella vaccine. Rev Med Virol 2014;24:254-73.

10.1002/rmv.178924687808

Kim SC, Won YH, Park JS, Jeon JS, Ahn JH, Song MJ, et al. Vaccine-type mutations identified in Varicella zoster virus passaged in cell culture. Virus Res 2018;245:62-8.

10.1016/j.virusres.2017.12.00429242077

Kim MH, Jeon JS, Kim IK, Park JS, Park H, Shin OS, et al. Characterization and phylogenetic analysis of Varicella-zoster virus strains isolated from Korean patients. J Microbiol 2017;55:665-72.

10.1007/s12275-017-7171-328752294

González-Motos V, Jürgens C, Ritter B, Kropp KA, Durán V, Larsen O, et al. Varicella zoster virus glycoprotein C increases chemokine-mediated leukocyte migration. PLoS Pathog 2017;13:e1006346.

10.1371/journal.ppat.100634628542541PMC5444840

Moffat JF, Zerboni L, Kinchington PR, Grose C, Kaneshima H, Arvin AM. Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol 1998;72:965-74.

10.1128/JVI.72.2.965-974.19989444989PMC124567

Plotkin SA, Orenstein WA, Offit PA. Vaccines, 6th ed. Elsevier, 2013.

Information

Publisher :The Korean Society for Microbiology
Publisher(Ko) :대한미생물학회
Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
Volume : 51
No :4
Pages :178-188
Received Date :2021. 08. 30
Revised Date :2021. 12. 06
Accepted Date : 2021. 12. 06
DOI :https://doi.org/10.4167/jbv.2021.51.4.178

JOURNAL OF BACTERIOLOGY AND VIROLOGY ISSN:1598-2467(Print) 2093-0429(Online)

All Issue